"Hepacivirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
Descriptor ID |
D016174
|
MeSH Number(s) |
B04.450.410 B04.820.250.475
|
Concept/Terms |
Hepacivirus- Hepacivirus
- Hepaciviruses
- Hepatitis C-Like Viruses
- Hepatitis C Like Viruses
- Hepatitis C-Like Virus
|
Below are MeSH descriptors whose meaning is more general than "Hepacivirus".
Below are MeSH descriptors whose meaning is more specific than "Hepacivirus".
This graph shows the total number of publications written about "Hepacivirus" by people in this website by year, and whether "Hepacivirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 4 | 1 | 5 |
1996 | 1 | 0 | 1 |
1997 | 2 | 1 | 3 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 3 | 0 | 3 |
2003 | 3 | 2 | 5 |
2004 | 2 | 2 | 4 |
2005 | 5 | 1 | 6 |
2006 | 3 | 1 | 4 |
2007 | 1 | 5 | 6 |
2008 | 4 | 0 | 4 |
2009 | 4 | 3 | 7 |
2010 | 3 | 3 | 6 |
2011 | 5 | 2 | 7 |
2012 | 7 | 7 | 14 |
2013 | 10 | 2 | 12 |
2014 | 8 | 9 | 17 |
2015 | 11 | 4 | 15 |
2016 | 9 | 6 | 15 |
2017 | 9 | 7 | 16 |
2018 | 10 | 4 | 14 |
2019 | 4 | 7 | 11 |
2020 | 3 | 5 | 8 |
2021 | 2 | 7 | 9 |
2022 | 2 | 19 | 21 |
2023 | 1 | 10 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepacivirus" by people in Profiles.
-
GSK-3? as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance. Intervirology. 2024; 67(1):6-18.
-
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. Ann Intern Med. 2023 12; 176(12):1648-1655.
-
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024 01; 22(1):72-80.e4.
-
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 09 01; 118(9):1609-1617.
-
Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clin Gastroenterol Hepatol. 2024 01; 22(1):91-101.e6.
-
Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States. Aliment Pharmacol Ther. 2023 07; 58(2):218-228.
-
Convergent antibody responses are associated with broad neutralization of hepatitis C virus. Front Immunol. 2023; 14:1135841.
-
Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series. Leuk Lymphoma. 2023 04; 64(4):900-903.
-
Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023 02 18; 76(4):592-599.
-
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor. Cell Rep. 2023 02 28; 42(2):112044.